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Case report
Correct donor D typing is critical to prevent recipient 
alloimmunization. No method can detect all variants, and the 
immunogenicity of many variants is unknown. Routine ABO and 
D serologic typings are performed in our laboratory by automated 
microplate testing. Until 2011, routine confirmation of D– status 
of first-time donors was performed by the manual tube indirect 
antiglobulin test (IAT); this was replaced by automated solid-
phase testing including weak D testing by IAT. Selected donors are 
investigated by other methods. We describe four weak D type 67 
(RHD*01W.67) donors whose samples tested as D– by automated 
microplate and manual methods but were later determined to 
be D+ by automated solid-phase and RHD gene analysis. Solid-
phase serologic and molecular typing results of all four donors 
were identical. It was identified that the donors are of English-
Irish descent; two are brothers and the others are cousins. 
Transfusion of blood from one of these donors likely resulted in 
alloimmunization to D in one of three recipients tested since no 
other documented exposures were identified. Lookback studies 
determined that two other D– recipients were not alloimmunized. 
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The D antigen is one of the most immunogenic and 
clinically significant blood group antigens known.1 Substantial 
variability is seen in the RHD gene, with over 160 different 
alleles described. Mutations affecting the intracellular and 
transmembrane domain of the D molecule usually lead to 
weakened expression of D, and there are now more than 76 
“weak D” variants listed in the Rh database (http://rhesusbase.
atspace.com), recognized by the International Society for 
Blood Transfusion Working Party on Blood Group Antigens, 
and reported in allele terminology.2
Correct donor D typing is crucial to prevent recipient 
alloimmunization. An undetected serological weak D 
phenotype associated with a variant RHD genotype may 
increase the risk of alloimmunization to D when transfused 
to a D– recipient. Unfortunately, commonly used D typing 
strategies, including commercially available serologic methods 
and absorption/elution studies, are unable to detect all D 
variants, and little is known about the immunogenicity of rare 
variants.3,4 Some information may be obtained by investigation 
of donors associated with a possible alloimmunization event.5 
After discovery of an index case, lookback may be done on 
previous donations from donors found to have the variant D 
antigen to determine if other D– recipients have also been 
alloimmunized.
RHD*01W.67 was identified on large-scale population 
genotyping and entered into the Rh database in 2008 by Flegel 
et al. in Germany (GenBank Accession: FM201787).6,7 This 
initial report described an association with a cE haplotype. 
RHD*01W.67 is the result of a nucleotide substitution at 
position c.722C>T on exon 5 (RHD*722T). This missense 
mutation results in a single amino acid change at position 
241 in the red blood cell (RBC) transmembrane protein 
segment (p.Thr241IIe).8 Many RHD variant alleles, classified 
as predicting both weak and partial antigens, involve amino 
acid substitutions in exon 5 alone. At least 11 other nucleotide 
changes in exon 5 resulting in variant D antigens have been 
described. Of these, two variants are within two amino 
acids of the RHD*01W.67 mutation in the transmembrane 
protein segment. To date, there have been no reports on 
the immunogenicity of the RHD*01W.67 variant and no 
description of the expected testing results by manual or 
automated hemagglutination methods.
Recently, anti-D was detected in a group O, D–, male 
patient secondary to the transfusion of three D– RBC 
units. On genotyping, one of the donors was found to be 
RHD*01W.67. Three other donors related to the propositus 
were also identified as RHD*01W.67 and had typed as D– 
on the initial automated testing platform.9 Lookback studies 
were performed on the RHD*01W.67 RBC units to further 




ABO and D testing are performed on an automated 
microplate hemagglutination test system (PK7300™; 
Beckman Coulter, Fullerton, CA). The two anti-D reagents used 
since 2008 are licensed for donor weak D testing: an anti-D 
monoclonal blend reagent (IgM and IgG human monoclonal 
blend, composed of clones P3X61, P3X21223B10, P3X290, and 
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P3X35; DIAGAST, Loos Cedex, France) and an anti-D (PK1) 
monoclonal IgM reagent (clone P3X61; DIAGAST). As per the 
package inserts, if testing with one or both of the D antisera 
shows a positive result, the final interpretation is D+; two 
negative results are interpreted as D–; and any indeterminate 
result is interpreted as “No Type Determined.” Confirmation 
of D– status of first-time donors was performed by the 
manual tube indirect antiglobulin test (IAT), replaced in 2011 
by a second automated solid-phase test (Galileo; Immucor, 
Norcross, GA), following manufacturer’s instructions and 
the reagent package inserts. Weak D testing was performed 
by the IAT using one of the Immucor monoclonal D reagents 
(anti-D Series 4 [IgG, IgM monoclonal blend, clones MS201 
and MS26]).
mAnuAl testing
Donor blood samples testing weak D+ on the Galileo 
were investigated by manual serologic methods (tube testing) 
performed by immediate spin and IAT using four different 
anti-D reagents: IgM (GAMA401) and IgG (F8D8) monoclonal 
blend (Gamma-clone, Immucor); IgM (D175-2) and IgG (D415 
1E4) monoclonal blend (Novaclone, Dominion Biologicals 
Limited, Dartmouth, Nova Scotia, Canada); Immucor anti-D, 
Series 5 IgG, IgM monoclonal blend (Immucor) and anti-D 
Series 4 IgG, IgM monoclonal blend (Immucor). Absorption/
elution studies were performed using a polyclonal anti-D (Elu 
Kit Plus; Dominion Biologicals and Immucor), and partial 
D typing was performed using the ALBAclone Advanced 
Partial RhD Typing Kit (Alba Bioscience Limited, Penicuik, 
UK). All testing was performed following the manufacturers’ 
instructions.
genotyping And dnA sequencing
Donor blood or extracted DNA samples for RHD 
genotyping were sent to the Grifols/Progenika reference 
laboratory (Medford, MA) and analyzed by the Progenika 
BLOODchip reference assay that interrogates 100 D variants 
including 20 weak D alleles. Manual genomic DNA extraction 
was done using the QIAamp DNA Mini Kit (QIAGEN, 
Germantown, MD), and DNA sequencing was performed by 
Grifols/Progenika using the standard Sanger dideoxy method 
with specific primers that bind to intron regions flanking RHD 
exons 5, 6, and 7, as described previously.8,10
Index Case
A group O, 67-year-old D– male patient with no 
documented history of transfusions was transfused two D– 
RBC units on February 9 and February 13, 2013, respectively. 
Antibody screens were negative prior to each transfusion as 
well as before a repeat screen on June 3, 2013. On June 5, 
2013, the patient underwent coronary artery bypass grafting 
and aortic valve replacement, and received one D– RBC unit 
perioperatively. On subsequent testing on June 9, 2013, the 
antibody screen became positive and anti-D was identified. 
The patient had significant postoperative anemia (hemoglobin 
nadir 6.6 mg/L), but there was no convincing evidence of 
hemolysis. This unexpected alloimmunization was reported to 
the blood supplier, and investigation was initiated on samples 
from the three donors as described earlier. The patient’s 
antibody screen was positive on repeat testing in August 2013 
and March 2014 with anti-D persisting in his plasma. Anti-
LW and anti-G were ruled out on the alloimmunized patient 
samples as per the referring hospital policies and procedures.
Results
On investigation, the two donors who had donated the 
RBC units transfused in February 2013 were confirmed to be 
D– on serologic testing and genotyping. The donor of the RBC 
unit transfused on June 5, 2013 (Donor 1) was found to be D+ 
by Galileo IAT and by manual IAT with D1 and D2 antisera 
(Table 1). This donor’s first donation was in 2007, prior to 
the implementation of a second automated screening test. On 
BLOODchip testing, the donor typed as D+. DNA sequencing 
demonstrated a c.722C>T change in exon 5 corresponding to 
RHD*01W.67.
Hospital transfusion services were asked to test for 
anti-D in D– recipients who were transfused with units 
from the implicated donors. Confirmation of no previous 
alloimmunization was also requested for these recipients 
as well as history of other blood product transfusion during 
the same admission as the alloimmunizing event. Standard 
serology methods were used.
Blood center records showed that in 2011, a first-time 
donor with the same surname had also typed as D– on the 
PK7300, and weak D+ on Galileo by IAT. Testing by manual 
tube IAT yielded variable results with various commercial 
anti-D antisera (Table 1, Donor 3). Further investigation 
demonstrated that this donor had the same genotyping 
results as Donor 1. In the next few months, two additional 
donors in the same geographic area, with the same surname, 
had indeterminate results on the PK7300. These donors had 
initial donations in 2001 (Donor 2) and 2008 (Donor 4) and 
several previous donations with D– testing results by PK7300, 
including earlier in 2013. Galileo, serologic, and molecular 
typing results were similar to Donors 1 and 3.
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By both serologic and molecular testing, all four donors 
were C+c+E–e+ (RHCE*Ce/RHCE*ce). Absorption/elution 
studies performed on two of the donors demonstrated the 
presence of D. The ALBAclone Advanced Partial RhD Typing 
Kit showed reactivity for all donor samples with a partial D 
(DFR) pattern (n = 3) or a nonspecific pattern (n = 1), suggesting 
that this kit has limitations in identifying the RHD*01W.67 
variant allele.
On lookback of the three repeat donors (Donors 1, 2, 
and 4), two additional D– recipients were tested and had not 
developed anti-D. Some of the implicated donor units were 
transfused to D+ patients; other patients had died or were not 
traceable.
On further questioning, it was determined that the four 
donors are of English-Irish descent; two are brothers and the 
others are distant cousins. All four donors live in a small town 
in Manitoba, Canada.
Discussion
The weak D type 67 (RHD*01W.67) variant, first described 
in Germany and reported in cis to cE, was found in four related 
Canadian blood donors of Anglo-Irish descent. On D typing, 
variable results were found on the PK7300 and by manual 
tube testing, whereas consistently positive results were found 
on automated solid-phase testing by IAT. Transfusion likely 
resulted in alloimmunization in one recipient and lack of 
alloimmunization in two other patients.
There are few published descriptions regarding the 
immunogenicity of RHD*01W.67 and the performance of 
current reagent and testing methods in recognizing this 
D variant. Identification of these four D-variant donors 
demonstrates that this red cell phenotype exists in Canada, 
may be associated with a haplotype not previously described, 
and is likely capable of inducing anti-D formation following 
transfusion to a D– recipient. Because the anti-D was detected 
several days post-transfusion, it is possible that the patient was 
alloimmunized by a previous transfusion episode at another 
hospital, and this transfusion resulted in secondary, rather 
than primary, alloimmunization. However, no documented 
previous transfusions were found or known by the recipient.
In these four donors, D testing yielded variable results 
on Beckman Coulter and manual testing, although results 
using the solid-phase Galileo testing platform were uniformly 
positive by IAT. In a study of the yield of adding this solid-
phase testing to initial D testing, we demonstrated that 1 in 
3900 D– donors tested on the Beckman Coulter platform 
was found by the IAT on the Galileo to have rare or novel D 
variants, including one example of RHD*01W.67 (Donor 3 
in this report).9 In these four recently identified donors, the 
molecular testing showed a RHD allele deletion by hybrid box 
detection and a RHD*01W.67 allele (RHD*722T). The RHCE 
Table 1. RHD*01W.67 identification in Canadian kindred of Anglo-Irish descent
Galileo†
Absorption/
elution Partial D typingDonor Genotype Basis for discovery PK7300 D testing Weak D (IAT) Manual method‡
1 RHCE*Ce/
RHCE*ce






































































† Galileo implemented in 2011 for first-time D– donors, and used for investigation only except for Donor 3 at time of first donation.
‡ D1 = Immucor Gamma-clone Monoclonal Blend; D2 = DBL Novaclone Monoclonal Blend; D3 = Immucor Series 5 Monoclonal Blend; D4 = Immucor Series 4 
Monoclonal Blend. For repeat donors, manual testing results shown are from several different donations.
§ This positive result was due to one test result being “?” and one test result being “+.”
IAT = indirect antiglobulin test; NEG = negative; POS = positive; DFR = partial RhD; IND = indeterminate; NT = not tested.
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allele analysis predicted a C+c+E–e+ phenotype different 
from the E+ phenotype described in the initial report of this 
variant.7 This also raises the interesting possibility of a “C-in-
trans” to RHD (Ceppellini effect), which further reduces an 
already weak D expression.11 Further study to confirm the 
donor haplotypes would be necessary to demonstrate accurate 
allele orientation.
The Progenika BLOODchip reference assay detects over 
100 variant D alleles, including 20 weak D alleles. Probes for 
weak D type 67 are not included in either the BLOODchip or 
the Bioarray RHD BeadChip automated testing platform. This 
result emphasizes the need to interpret genotyping data in 
conjunction with serologic and clinical data and to collaborate 
with an immunohematology reference laboratory as needed to 
resolve a discrepant type if the primary transfusion laboratory 
does not have the capacity or expertise to complete the required 
additional testing.4,12
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